Research shows patients taking weight-loss drugs like Ozempic and Wegovy are more likely to have food left in the stomach or stool left in the bowel before an endoscopy or colonoscopy.

In real-world settings multiple factors contribute to non-persistence, including adverse effects, high cost-sharing and weight loss not meeting patients' expectations.

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.

Glucagon-like peptide 1 receptor agonists, more commonly known as GLP-1 medications, have dominated headlines for their success in managing blood sugar levels and drastically reducing weight. Between new clinical trial results and a boom in celebrity usage, the popularity of the medications increased drastically over the past two years.

People with type 2 diabetes and obesity who develop kidney disease may benefit more from bariatric surgery than from GLP-1 drugs when it comes to preserving kidney function, a new study finds.

Some oncologists are turning to GLP-1 agents to help patients shed excess pounds, with the goal of improving cancer outcomes. But data on the practice remain limited.

New research suggests GLP-1 medications like Ozempic may help reduce several health risks in addition to treating type 2 diabetes and obesity.